Invesco Mutual Fund has launched the Invesco India Pharma and Healthcare Fund, an open ended equity scheme investing in the pharma, healthcare and allied sectors. Invesco Asset Management (India) Private Limited manages the fund. The NFO opens on 18 August 2026 and closes on 1 September 2026.
The scheme aims for long term capital appreciation by investing predominantly in equity and equity related securities of pharma, healthcare and allied sector companies, in India and overseas. It follows an active strategy across large, mid and small cap businesses.
If you already track India’s healthcare growth story, or want a single sector allocation alongside a diversified core portfolio, here is what the scheme document says before the NFO closes.
Invesco India Pharma and Healthcare Fund NFO details
Detail | Information |
Fund name | |
Fund type | Open ended equity scheme |
Category | Sectoral fund (pharma, healthcare and allied sectors) |
Nature of scheme | Actively managed, diversified across market capitalisation |
Benchmark | BSE Healthcare TRI |
Fund manager | |
NFO opens | 18 August 2026 |
NFO closes | 1 September 2026 |
Allotment / reopening | Not available. Reopens for continuous sale and repurchase within 5 business days from allotment. |
Minimum investment | Rs 1,000, multiples of Re 1 thereafter |
Additional investment | Rs 1,000, multiples of Re 1 thereafter |
SIP amount | Not separately specified; general minimum application amount applies |
NAV during NFO | Rs 10 per unit |
Risk level | Very high risk, scheme and benchmark |
Stamp duty | Not available |
Entry load | Nil |
Exit load | 0.50% within 3 months of allotment; nil after; nil for plan switches |
Invesco Asset Management (India) details
Detail | Information |
AMC name | Invesco Asset Management (India) Private Limited |
AUM (combined onshore and offshore, Sep 2025) | Approximately Rs 1,48,358 crore |
Website | |
Registered office | Unit No: 2101 A, 21st floor, A – Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai – 400 013 Maharashtra, India. |
Contact number | 1800 209 0007 (toll free) |
Source: AMFI India, New fund offer : Invesco India Pharma and Healthcare Fund
What has Invesco India launched?
This is a sectoral equity fund, investing within one theme. The universe spans pharmaceutical manufacturers, hospitals, diagnostics, medical equipment, biotechnology, healthcare analytics, and wellness businesses, in India and abroad.
The objective is long term capital appreciation, not income, with no assurance it will be met. The fund is actively managed, so the manager selects stocks rather than tracking an index, moving across large, mid and small cap healthcare businesses. The scheme needs Rs 10 crore during the NFO to be viable, failing which subscription money is refunded.
How does the Invesco India Pharma and Healthcare Fund strategy work?
Rather than tracking an index, the manager builds the portfolio bottom up, researching individual businesses against the fund’s asset allocation limits:
Step | What happens? |
1 | Define the universe: pharma, healthcare, hospitals, diagnostics, biotechnology and allied businesses |
2 | Research companies on fundamentals, management and growth prospects within these sub-segments |
3 | Build a diversified portfolio across large, mid and small cap healthcare stocks |
4 | Allocate up to 20% to other equities, or debt and money market instruments, for liquidity |
5 | Use derivatives, within limits, mainly for hedging and portfolio balancing |
6 | Monitor sector and stock risk continuously and adjust as healthcare themes evolve |
Let’s understand through an example
Say an investor puts Rs 10,000 into the NFO at the offer price of Rs 10 per unit and receives 1,000 units. That money is pooled with other investors’ contributions and deployed per the scheme’s asset allocation pattern, mostly into pharma and healthcare shares. The value of those 1,000 units then moves with the combined market value of the underlying portfolio each business day, after expenses. This illustration only explains the mechanism; it is not a return projection.
Invesco India Pharma and Healthcare Fund portfolio allocation
Instrument | Minimum | Maximum |
Equity and equity related instruments in pharma, healthcare and allied sectors | 80% | 100% |
Other equity and equity related instruments | 0% | 20% |
Debt and money market instruments | 0% | 20% |
Units issued by InvITs | 0% | 10% |
Investment strategy
Stock selection spans pharmaceutical manufacturers, hospital and diagnostic chains, medical equipment makers, biotechnology firms, healthcare analytics companies, and wellness businesses supporting the pharma value chain, directly or indirectly.
The scheme can also invest overseas, intending to deploy up to USD 25 million within six months of NFO closure, subject to regulatory headroom. Risk controls rely on diversification across sub-segments rather than concentration in a handful of names. Derivatives may be used for hedging and portfolio balancing, within SEBI limits.
Potential benefits of Invesco India Pharma and Healthcare Fund
Potential benefit | Why does it matter? |
Focused exposure to a growth sector | India’s healthcare and pharma businesses benefit from rising domestic demand, exports and innovation led growth |
Active, research led stock selection | The manager can move between large, mid and small healthcare businesses rather than replicate an index |
Diversification role in a wider portfolio | A single sector allocation can complement, rather than duplicate, a diversified core equity holding |
Access to emerging sub-segments | The fund can invest in diagnostics, wellness and healthcare technology names, not just manufacturers |
Key risks
Risk | What does it mean? |
Market risk | Equity prices, including pharma and healthcare stocks, can fall as well as rise with broader conditions |
Concentration risk | One sector focus means weak pharma and healthcare performance affects the whole portfolio more than a diversified fund |
Liquidity risk | Lower trading volumes in some healthcare stocks may affect how quickly the fund trades at a fair price |
Derivative risk | Derivatives used for hedging or balancing carry their own execution and counterparty risk |
Who may consider Invesco India Pharma and Healthcare Fund?
Investor type | Why it may fit |
Long horizon investors, 5 years or more | Healthcare sector cycles can take years to play out; a short horizon rarely suits a concentrated theme |
Investors with an existing diversified portfolio | A single sector fund works better as a satellite than a first equity holding |
Investors comfortable with very high risk | Concentration in one sector means sharper swings than a diversified equity fund |
Who may not find it suitable?
Investor type | Why it may not fit |
First time equity investors seeking a core holding | Sector concentration removes the diversification a first equity investment usually needs |
Investors with a horizon under 3 months | The exit load applies within 3 months of allotment |
Investors uneasy with sector level swings | A single sector portfolio can move more sharply than a diversified fund in either direction |
Comparison with traditional investment options
Option | Risk | Return potential | Volatility | Liquidity | Suitable investor |
Fixed deposit | Low | Low to moderate | Low | Moderate (premature withdrawal penalty) | Capital protection seekers |
Debt mutual fund | Low to moderate | Moderate | Low to moderate | High | Short to medium term goals |
Hybrid fund | Moderate | Moderate | Moderate | High | Balanced risk appetite |
Diversified equity fund | High | High | High | High | Long term wealth creation across sectors |
This fund (sectoral) | Very high | High, tied to one sector | High | High | Long term, sector conviction investors |
Invesco India Pharma and Healthcare Fund review by Zenith Finserve
This fund suits investors who already have a diversified core equity portfolio and want a satellite position tied to India’s healthcare growth theme, typically with a horizon of 5 years or longer and no need for interim liquidity. As a single sector, actively managed scheme carrying very high risk, it is not designed to be anyone’s first or only equity holding.
Its ability to invest across pharma, hospital, diagnostic, biotechnology and wellness sub-segments gives it more room to move than a narrowly defined pharma only fund, though one sector concentration risk remains, and the overseas allocation adds a currency linked dimension to that risk.
As with any new scheme, there is no track record yet. Weigh your goal timeline, existing sector exposure and comfort with concentrated volatility before applying, rather than treating sector momentum alone as the reason to invest.
How Zenith Financial Management can help
At Zenith Financial Management, we follow a process driven investment framework. We assess your goals, cash flows, risk profile, time horizon, existing investments, loans and tax situation before suggesting investments. We align our investment suggestions with your financial objectives and review them periodically to keep them suitable as your circumstances change.
Read more about our approach on our investment planning services page, or explore our mutual fund advisory services.
Similar NFOs on Zenith
Zenith has not yet covered another pharma or healthcare NFO, so no directly comparable article exists yet. For related reading on active equity and single sector, very high risk mandates:
TRUSTMF Large & Mid Cap Fund NFO: a recent active equity launch, for contrast.
HDFC Nifty Metal ETF FOF NFO: another single sector, very high risk launch, though passive.
Edelweiss Nifty REITs & Realty Index Fund NFO: also single theme and very high risk.
Frequently asked questions
What is Invesco India Pharma and Healthcare Fund?
An open ended equity scheme from Invesco Mutual Fund investing predominantly in pharma, healthcare and allied sector shares, aiming for long term capital appreciation.
When does the Invesco India Pharma and Healthcare Fund NFO open and close?
It opens on 18 August 2026 and closes on 1 September 2026.
What is the minimum investment amount?
Rs 1,000, and multiples of Re 1 thereafter, for both first and additional purchases.
Is Invesco India Pharma and Healthcare Fund NFO good to invest in?
This is a factual overview, not a recommendation. Fit depends on your goals, horizon, existing sector exposure and comfort with concentrated, very high risk.
What does the fund invest in?
Mainly equity and equity related instruments of pharma, healthcare, hospital, diagnostic and biotechnology businesses, with room for other equities, debt and InvIT units.
What is the exit load?
0.50% if redeemed or switched out within 3 months of allotment; nil after that.
Who is the fund manager?
Mr Taher Badshah, Chief Investment Officer at Invesco Asset Management (India).
What is the benchmark?
The BSE Healthcare TRI, the SEBI mandated first tier benchmark for this category.
How risky is Invesco India Pharma and Healthcare Fund?
Both the scheme and its benchmark carry very high risk, reflecting concentration in pharma and healthcare stocks.
Invesco India Pharma and Healthcare Fund review: what should I check before investing?
Your existing sector exposure, goal horizon and comfort with a single sector’s volatility, since this fund does not replace a diversified core equity holding.
